Redx Pharma to be valued at £55m on AIM debut
Date added:
26/03/2015
DRUG development company Redx Pharma will be valued at just over £55m when shares begin trading on Friday. The Liverpool-based biotech company, which also has an operation at Alderley Bark, Cheshire, has placed17,647,059 new ordinary shares at 85p per share, raising £15m, £13.5m net. Chief executive Neil Murray said he was pleased with the response to Redx after institutional roadshows, and said is looking forward to delivering on the company's strategy to create a sustainable and profitable business. "This pla....
Back to all news